DexCom, Inc. $DXCM Shares Purchased by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 27.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,280 shares of the medical device company’s stock after purchasing an additional 1,370 shares during the period. Cullen Frost Bankers Inc.’s holdings in DexCom were worth $548,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Golden State Wealth Management LLC increased its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom during the first quarter worth approximately $27,000. Anderson Financial Strategies LLC acquired a new position in DexCom during the first quarter worth approximately $37,000. Alpine Bank Wealth Management acquired a new position in DexCom during the first quarter worth approximately $40,000. Finally, Private Trust Co. NA increased its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock opened at $70.33 on Friday. The company has a market capitalization of $27.58 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47. The firm has a fifty day simple moving average of $72.37 and a 200-day simple moving average of $77.78. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 over the last ninety days. 0.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Mizuho boosted their price objective on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Cowen reiterated a “buy” rating on shares of DexCom in a research note on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Friday. Finally, Robert W. Baird decreased their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research note on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $97.19.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.